[1] Broumand B. Diabetes: changing the fate of diabetics in the dialysis unit. Blood Purif. 2007;25(1):39-47. [2] Fasseas P, Brilakis ES, Leybishkis B, et al. Association of carotid artery intima-media thickness with complex aortic atherosclerosis in patients with recent stroke. Angiology. 2002;53(2):185-189.[3] Dursun B, Dursun E, Capraz I, et al. Are uremia, diabetes, and atherosclerosis linked with impaired antioxidant mechanisms J Investig Med. 2008;56(2):545-552.[4] Simon A, Gariepy J, Chironi G, et al. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. JHypertens. 2002;20(2):159-169. [5] Nakamura T, Matsuda T, Kawagoe Y, et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism. 2004;53(10):1382-1386.[6] 匡鼎伟,丁峰,薛骏, 等.维持性血透患者颈动脉内膜中层厚度增厚及其影响因素分析[J].中华肾脏病杂志,2005,21(10):577-581. [7] Joki N, Hase H, Saijyo T, et al. Combined assessment of cardiac systolic dysfunction and coronary atherosclerosis used to predict future cardiac deaths after starting hemodialysis. Am J Nephrol. 2003;23(6):458-465. [8] Yokoyama H, Aoki T, Imahori M, et al. Subclinical atherosclerosis is increased in type 2 diabetic patients with microalbuminuria evaluated by intima-media thickness and pulse wave velocity. Kidney Int. 2004;66(1):448-454.[9] Kobayashi S, Maejima S, Ikeda T, et al. Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2000; 15 (1):65-70. [10] Elokely A, Shoukry A, Ghonemy TA, et al. Association of adiponectin with cardiovascular events in diabetic and non-diabetic hemodialysis patients. Saudi J Kidney Dis Transpl. 2012;23(4):736-742.[11] Bondar' IA, Klimontov VV. Treatment of diabetes mellitus in dialysis patients. Ter Arkh. 2011;83(12):73-77. [12] Abe M, Okada K, Kikuchi F, et al. Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2-diabetic patients undergoing hemodialysis. Clin Nephrol. 2008;70(3):220-228.[13] Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis. 2007;50(5):865-879.[14] Emoto M, Nishizawa Y, Maekawa K, et al. Homeostasis model assessment as a clinical index of insulin resistance in type2 diabetic patients treated with sulfonylureas. Diabetes Care. 1999;22:818-822.[15] Pascazio L, Bianco F, Giorgini A, et al.Echo color Doppler imaging of carotid vessels in hemodialysis patients: evidence of high levels of atherosclerotic lesions. Am J Kidney Dis. 1996;28(5):713-720. [16] Nakamura T, Matsuda T, Kawagoe Y, et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism. 2004;53(10):1382-1386.[17] Zhang L, Zhao F, Yang Y, et al. Association between carotid artery intima-media thickness and early-stage CKD in a Chinese population. Am J Kidney Dis. 2007;49(6):786-792.[18] Pignoli P, Tremoli E, Poli A, et al. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation. 1986;74(6):1399-1406.[19] Hung AM, Ikizler TA. Factors determining insulin resistance in chronic hemodialysis patients. Contrib Nephrol. 2011;171:127-134. [20] Takenaka T, Kanno Y, Ohno Y, et al. Key role of insulin resistance in vascular injury among hemodialysis patients. Metabolism. 2007;56(2):153-159. [21] Toprak O, Cirit M, Yesil M, et al. Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease. Nephrol Dial Transplant. 2007;22(3):819-826. [22] Bodlaj G, Berg J, Pichler R, et al. Prevalence, severity and predictors of HOMA-estimated insulin resistance in diabetic and nondiabetic patients with end-stage renal disease. J Nephrol. 2006;19(5):607-612.[23] Borissova AM, Djambazova A, Todorov K, et al. Effect of erythropoietin on the metabolic state and peripheral insulinsensitivity in diabetic patients on haemodialysis. Nephrol Dial Transplant.1993;8(1):93.[24] Shoji T, Emoto M, Nishizawa Y.HOMA index to assess insulin resistance in renal failure patients. Nephron. 2001;89: 348-349.[25] Gullu H, Erdogan D, Caliskan M, et al. Interrelationship between noninvasive predictors of atherosclerosis: transthoracic coronary flow reserve, flow-mediated dilation, carotid intima-media thickness, aortic stiffness, aortic distensibility, elastic modulus, and brachial artery diameter. Echocardiography. 2006;23(10):835-842.[26] Campuzano R, Moya JL, García-Lledó A, et al. Endothelial dysfunction, intima-media thickness and coronary reserve in relation to risk factors and Framingham score in patients without clinical atherosclerosis. J Hypertens. 2006;24(8): 1581-1588.[27] Hung AM, Sundell MB, Egbert P, et al. A comparison of novel and commonly-used indices of insulin sensitivity in African American chronic hemodialysis patients. Clin J Am Soc Nephrol. 2011;6(4):767-774. [28] Cade C; Norman AW. Vitamin D3 improves glouse intolerance and insulin secretion in the vitamin D deficient rat in vivo. Endocrinology. 1986;119:84-90.[29] Liao MT, Sung CC, Hung KC, et al. Insulin resistance in patients with chronic kidney disease. J Biomed Biotechnol. 2012;2012:691369. [30] Zang L, Fu P, Huang YQ, et al. [Vitamin D deficiency and carotid artery intima-media thickness and coronary calcification in patients with diabetic Nephropathy. Sichuan Da Xue Xue Bao Yi Xue Ban. 2012;43(3):420-424, 450. [31] Falaknazi K, Tajbakhsh R, Sheikholeslami FH. Evaluation of association between intima-media thickness of the carotid artery and risk factors for cardiovascular disease in patients on maintenance hemodialysis. Saudi J Kidney Dis Transpl. 2012;23(1):31-36.[32] Kim KJ, Lee BW, Kim HM, et al. Associations between cardio-ankle vascular index and microvascular complications in type 2 diabetes mellitus patients. J Atheroscler Thromb. 2011;18(4):328-336. |